{"id":21226,"date":"2024-03-14T12:54:59","date_gmt":"2024-03-14T12:54:59","guid":{"rendered":"https:\/\/clinlabint.com\/?p=21226"},"modified":"2024-03-14T12:55:47","modified_gmt":"2024-03-14T12:55:47","slug":"proscia-receives-us-fda-clearance-for-concentriq-ap-dx","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/proscia-receives-us-fda-clearance-for-concentriq-ap-dx\/","title":{"rendered":"Proscia receives US FDA clearance for Concentriq AP-Dx"},"content":{"rendered":"
\n

\r\n\"Forum<\/a>\r\n<\/div><\/p>\n<\/div><\/section><\/div>

\r\n\r\n\"\"<\/a>\r\n<\/div><\/p>\n<\/div><\/section>
\n

Proscia receives US FDA clearance for Concentriq AP-Dx<\/h1>\/ in Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Proscia, a leading provider of digital and computational pathology solutions, has received US FDA 510(k) clearance for its Concentriq AP-Dx. The digital pathology solution was cleared for the purpose of primary diagnosis and should be used with the Hamamatsu NanoZoomer S360MD Slide scanner in the United States.<\/strong><\/p>\n

<\/p>\n

Proscia\u2019s Concentriq AP-Dx is a comprehensive diagnostic software solution that immerses pathologists in an intuitive experience for viewing, interpreting, and managing whole slide images with efficiency and confidence. It can also streamline collaboration, broadening access to expertise. Concentriq AP-Dx was designed to be used in clinical settings of all sizes, from individual reference laboratories to the largest hospital systems.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n
\n

In support of its 510(k) clearance, Proscia conducted a multi-site clinical study at PathGroup, South Bend Medical Foundation, and Spectrum Healthcare Partners. The study demonstrated that diagnoses made on Concentriq AP-Dx are non-inferior to traditional glass slide reads. Relative to ground truth data, the difference in major discordance rates for slides read digitally and for slides read using the microscope was -0.1%, which is among the strongest findings of similar publicly available studies.<\/p>\n

\u201cThis regulatory milestone reflects our tireless commitment to our mission of perfecting cancer diagnosis,\u201d said David West, Proscia\u2019s CEO. \u201cPathologists are facing more pressure than ever before in the fight against some of humanity\u2019s biggest challenges. With 510(k) clearance, we can help more laboratories improve the pathologist experience and better serve their patients.\u201d<\/p>\n

Up to 70% of clinical decisions depend on pathology. Digital pathology shifts the standard from microscope to high-resolution images each containing over 1 billion pixels that tell the story of a patient\u2019s disease and hold the keys to advancing precision medicine. It is also driving powerful efficiency gains that help laboratories to overcome systemic challenges; hiring for pathologists is near an all-time high as the number of new cancer cases per year in the U.S. is expected to cross 2 million in 2024 for the first time.<\/p>\n

CE-IVDR certification<\/h4>\n

In addition to its 510(k) clearance, Proscia was the first company to achieve CE-IVDR certification to advance primary diagnosis in the European Union. The company also has a product licensed in Canada and cleared in the United Kingdom among other countries. More than 10,000 pathologists and scientists, including those at top diagnostic laboratories and 14 of the top 20 pharmaceutical companies, trust Proscia\u2019s software.<\/p>\n

Concentriq AP-Dx webinar<\/h4>\n

To learn more about Concentriq AP-Dx and see a live demo, register for Proscia\u2019s webinar. \u201cWelcome to Concentriq AP-Dx\u201d will take place on Friday, March 8 at 12PM EST \u2013 visit: http:\/\/tinyurl.com\/4m5w2tds<\/a><\/p>\n

For more information about DeepMirror, visit: www.proscia.com<\/a><\/p>\n

Digital issue: Please click here<\/a> for more information<\/p>\n<\/div><\/section>
\n